SEC Comment Letter for Elicio Therapeutics, (ELTX) — Mar 6, 2026
Elicio Therapeutics, Inc.
Date: March 6, 2026 · CIK: 0001601485 · Accession: 0000000000-26-002334
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293861
Letter
Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed February 27, 2026 File No. 333-293861 Dear Robert Connelly:
March 6, 2026
Robert Connelly President & Chief Executive Officer Elicio Therapeutics, Inc. 451 D Street, 5th Floor Boston, MA 02210
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Daniel Bagliebter, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 6, 2026 Robert Connelly President & Chief Executive Officer Elicio Therapeutics, Inc. 451 D Street, 5th Floor Boston, MA 02210 Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed February 27, 2026 File No. 333-293861 Dear Robert Connelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Bagliebter, Esq. </TEXT> </DOCUMENT>